Curevac announces decision of german federal patent court in broad patent litigation with biontech se

Validity of curevac patent ep 1 857 122 b1 denied by german federal patent court after nullity action filed by biontech se decision does not affect ongoing litigation in germany regarding seven other intellectual property rights, covering strong foundational as well as covid-19-specific mrna innovation curevac to appeal before the german federal court of justice, while remaining confident in the strength of its broad intellectual property portfolio tÜbingen, germany and boston, ma / accesswire / december 19, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that the nullity action filed by biontech se against the german part of curevac patent ep 1 857 122 b1 was granted by the german federal patent court.
CVAC Ratings Summary
CVAC Quant Ranking